Last reviewed · How we verify
DTG/ABC/3TC
This is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes.
This is a fixed-dose combination of three antiretroviral drugs that work together to suppress HIV replication by inhibiting reverse transcriptase and integrase enzymes. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in adolescents and children (weight-based formulations).
At a glance
| Generic name | DTG/ABC/3TC |
|---|---|
| Sponsor | Harvard School of Public Health (HSPH) |
| Drug class | Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV integrase, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
DTG (dolutegravir) is an integrase strand transfer inhibitor that blocks HIV integrase, preventing viral DNA from integrating into the host genome. ABC (abacavir) and 3TC (lamivudine) are nucleoside reverse transcriptase inhibitors that block the reverse transcriptase enzyme, preventing conversion of viral RNA to DNA. Together, these three agents provide complementary mechanisms to suppress HIV viral load.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in adolescents and children (weight-based formulations)
Common side effects
- Hypersensitivity reaction (abacavir)
- Nausea
- Diarrhea
- Headache
- Insomnia
- Rash
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study of GS-3242 in Participants With HIV-1; Substudy-05 (PHASE1)
- POC HIV Testing and Early DTG Use for Infants (PHASE4)
- Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (PHASE3)
- Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults (PHASE3)
- Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTG/ABC/3TC CI brief — competitive landscape report
- DTG/ABC/3TC updates RSS · CI watch RSS
- Harvard School of Public Health (HSPH) portfolio CI